Indication: Neurofibromatosis Type 1 (NF1)

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity

Sub-indication: Neurofibromatosis Type 1 (NF1)

Drug Study

Principal Investigator: Alexander Asamoah, M.D., Ph.D.
Norton Children's Genetics Center, affiliated with the UofL School of Medicine

Sponsor: SpringWorks Therapeutics, Inc

Learn more at ClinicalTrials.gov

Search our entire site.